Objective: To provide updated evidence-based recommendations for the preventive treatment of migraine headache. The clinical question addressed was: What pharmacologic therapies are proven effective for migraine prevention?
Epidemiologic studies suggest approximately 38% of migraineurs need preventive therapy, but only 3%-13% currently use it. 1 In 2000, the American Academy of Neurology (AAN) published guidelines for migraine prevention. 2, 3 Since then, new clinical studies have been published on the efficacy and safety of migraine preventive therapies. This guideline seeks to assess this new evidence to answer the following clinical question: For patients with migraine, which pharmacologic therapies are proven effective for prevention, as measured by reduced migraine attack frequency, reduced number of migraine days, or reduced attack severity? This article addresses the safety and efficacy of pharmacologic therapies for migraine prevention.
Separate guidelines are available for botulinum toxin. 4 The 2008 guideline included a Level B recommendation that botulinum toxin was probably ineffective for treatment of episodic migraine. A new guideline is in development. An updated guideline on nonsteroidal anti-inflammatory drugs 5 and complementary alternative treatments has been approved for publication as a companion to this guideline. 5 
DESCRIPTION OF THE ANALYTIC PROCESS
The AAN and the American Headache Society participated in the development process. An author panel of headache and methodologic experts was assembled to review the evidence. Computerized searches of the MEDLINE, PsycINFO, and CINAHL databases identified new studies (published in English). The search strategy used the MeSH term "headache" (exploded) and a published search strategy for identifying randomized controlled trials (RCTs) published between June 1999 and May 2007. Additional MEDLINE searches revealed studies published through May 2009, which were reviewed and included as supplemental articles.
Studies of pharmacologic agents available in the United States were included in the analysis if they randomized adult patients with migraine to the agent under study or a comparator drug (including placebo) and utilized masked outcome assessment. At least 2 panelists independently reviewed each study and rated it according to the AAN therapeutic classification of evidence scheme (appendix e-3 on the Neurology ® Web site at www.neurology.org). Differences in ratings were resolved by author panel discussion. • Assessed the efficacy of therapeutic agents for headache other than episodic migraine in adults • Assessed acute migraine treatment, migraine aura treatment/prevention, or nonpharmacologic treatments (e.g., behavioral approaches) • Used quality of life measures, disability assessment, or nonstandardized outcomes as primary efficacy endpoints • Tested the efficacy of drugs not available in the United States
ANALYSIS OF EVIDENCE
Since the 2000 guideline publication, the AAN revised its evidence classification criteria to include study completion rates. Studies with completion rates below 80% were downgraded; several studies in the original guideline have thus been downgraded.
We found no new Class I or II studies published for acebutolol, atenolol, bisoprolol, carbamazepine, Table 1 Classification of migraine preventive therapies (available in the United States) Abbreviations: ACE ϭ angiotensin-converting-enzyme; MRM ϭ menstrually related migraine; SSNRI ϭ selective serotoninnorepinephrine reuptake inhibitor; SSRI ϭ selective serotonin reuptake inhibitor; TCA ϭ tricyclic antidepressant. a Classification based on original guideline and new evidence not found for this report. b For short-term prophylaxis of MRM.
clonazepam, clonidine, clomipramine, fluvoxamine, guanfacine, nabumetone, nadolol, nicardipine, nifedipine, or protriptyline. Recommendations for these agents are based on the evidence reviewed in the original guideline (see 7 AEs included cough (26%; 10% discontinued treatment due to cough), dizziness (23%), and "tendency to faint" (10%). No serious AEs were reported.
Telmisartan. In a single Class II placebocontrolled trial, telmisartan 80 mg did not show a significant difference from placebo for reduction in migraine days (Ϫ1.65 vs Ϫ1.14). Conclusions. Lisinopril and candesartan are possibly effective for migraine prevention (1 Class II study each). Telmisartan is possibly ineffective for reducing the number of migraine days (1 negative Class II study).
Antiepileptic drugs. Divalproex. The original guideline found strong, consistent support (5 studies) for the efficacy of divalproex sodium and its corresponding compound, sodium valproate, for migraine prevention.
Since the 2000 publication, 1 double-blind, randomized, Class I placebo-controlled 12-week trial showed extended-release (ER) divalproex sodium 500 -1,000 mg/day had a mean reduction in 4-week migraine headache rate from 4.4/week (baseline) to 3.2/week (Ϫ1.2 attacks/week) in the ER divalproex sodium group and from 4.2/week to 3.6/week (Ϫ0.6 attacks/week) in the placebo group (CI 0.2-1.2; p ϭ 0.006). 9 No significant differences were detected between groups in the number of treatment-emergent AEs.
Clinical context. In most headache trials, patients taking divalproex sodium or sodium valproate reported no more AEs than those on placebo. However, weight gain has been clinically observed with divalproex sodium long-term use. 9, 10 Treatment with these agents requires careful follow-up and testing because of pancreatitis, liver failure, and teratogenicity risks.
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Gabapentin. Since the 2000 publication, a Class III study 12 reported that a stable gabapentin dose (4-week titration phase to 2,400 mg/day; 8-week maintenance phase) significantly reduced the median monthly migraine rate vs placebo on the basis of a modified intention-to-treat analysis.
Lamotrigine. The original guideline reported a single Class I lamotrigine study 13 that failed to show a significant effect for migraine prevention. A second, new Class I study comparing lamotrigine 50 mg/day with placebo or topiramate 50 mg/day reported lamotrigine was not more effective than placebo (for both primary endpoints) and was less effective than topiramate in reducing migraine frequency and intensity. 14 The primary outcome measure (responder rate: Ն50% monthly migraine frequency reduction) was 46% for lamotrigine vs 34% for placebo ( p ϭ 0.093, CI 0.02-0.26) and 63% for topiramate vs 46% for lamotrigine ( p ϭ 0.019, CI 0.03-0.31). Treatment-related AEs (rash, giddiness, sleepiness, and gastrointestinal intolerance) occurred in 10% of patients on lamotrigine.
Oxcarbazepine. One Class II trial evaluated the efficacy of oxcarbazepine (1,200 mg/day) vs placebo. Topiramate. Four Class I studies 14,16 -18 and 7 Class II studies 19 -25 report topiramate (50 -200 mg/day) is effective in migraine prevention.
In a Class I placebo-controlled study (mean topiramate dose 125 mg/day [range 25-200 mg/day]), patients given topiramate experienced a significantly lower 28-day migraine frequency vs with placebo (3.31 Ϯ 1.7 vs 3.83 Ϯ 2.1; p ϭ 0.002). 18 In a second placebo-controlled Class I double-crossover study (reviewed above), topiramate was more effective than placebo and lamotrigine for primary efficacy measures. 14 In the topiramate groups, 15% of patients experienced AEs, most commonly paresthesias, sleepiness, and gastrointestinal intolerance. The placebo group reported gastrointestinal intolerance (3%) and anorexia (3%).
Two additional Class I studies report topiramate is as effective as propranolol 16 or sodium valproate, 17 drugs previously established as effective for migraine prevention. In the first study, subjects given topiramate 50 mg/day had reduced mean migraine frequency (episodes/month) from baseline (6.07 Ϯ In a crossover Class I trial (2-month washout between therapies) comparing topiramate 50 mg/day with sodium valproate 400 mg/day, both groups showed improvement from baseline in headache frequency, intensity, and duration. 17 Average monthly migraine frequency decreased by 1.8 times with sodium valproate (baseline 5.4 Ϯ 2.5; posttreatment 3.6 Ϯ 2.1; CI 1.0 -2.6; p Ͻ 0.001), as compared with a 3-time reduction with topiramate (baseline 5.4 Ϯ 2.0; posttreatment 2.4 Ϯ 2.4; CI 2.1-3.9; p Ͻ 0.001). Headache intensity decreased by 3.7 with sodium valproate (baseline 7.7 Ϯ 1.2; treatment 4.0 Ϯ 2.1; CI 2.9 -4.6; p Ͻ 0.001), as compared with a reduction of 3.6 with topiramate (baseline 6.9 Ϯ 1.2, treatment phase 3.3 Ϯ 1.5; CI 2.9 -4.3; p Ͻ 0.001). The average headache episode duration decreased by 13.4 hours from baseline with sodium valproate (baseline 21.3 Ϯ 14.6; treatment 7.9 Ϯ 7.7; CI 7.5-19.3; p Ͻ 0.001) as compared with an 11.9-hour reduction with topiramate (baseline 17.3 Ϯ 8.4; treatment 5.4 Ϯ 6.4; CI 8.2-15.6; p Ͻ 0.001). The overall analysis of repeated-measures analysis of variance demonstrated no differences in monthly headache frequency, intensity, or duration after the first or second treatment rounds. Topiramate AEs were weight loss (18.8%), paresthesias (9.4%), or both (25%). Sodium valproate AEs were weight gain (34.5%), hair loss (3.1%), and somnolence (3.1%).
Results of 5 Class II studies support those of the Class I studies showing topiramate as effective for migraine prevention. 19 -25 Four studies demonstrated significant improvement over placebo 19, 20, 23, 24 ; one included an active comparator arm, suggesting equivalence of topiramate (100, 200 mg/day) and propranolol (160 mg/day). 20 Two studies comparing topiramate and amitriptyline (25-150 mg/day) reported no difference in efficacy for primary endpoints; however, amitriptyline was associated with a significant AE increase, and the amitriptylinetopiramate combination suggested improvement in depression scores vs monotherapy. 21, 22 In one of these studies, 21 the most common AEs were similar to those previously reported. One Class II placebo-controlled 24-week pilot study failed to show a difference in efficacy between topiramate 200 mg and placebo. 26 Conclusions. Divalproex sodium and sodium valproate are established as effective in migraine prevention (multiple Class I studies). Data are insufficient to determine the effectiveness of gabapentin (1 Class III study). Lamotrigine is established as ineffective for migraine prevention (2 Class I studies). Oxcarbazepine is possibly ineffective for migraine prevention (1 Class II study). Topiramate is established as effective for migraine prevention (4 Class I studies, multiple Class II studies; 1 negative Class II study). Topiramate is probably as effective for migraine prevention as propranolol (1 Class I study), sodium valproate (1 Class I study), and amitriptyline (2 Class II studies).
Antidepressants. Fluoxetine. In the original guideline, 1 Class II study 27 showed fluoxetine (racemic) was significantly better than placebo for migraine prevention, but the results were not duplicated in a second study. 28 Since the original guideline, a Class II study has shown fluoxetine 20 mg/day was more effective than placebo in reducing total pain index scores (calculated as [
, where D1, D2, and D3 represent headache hours calculated in a month, with pain intensity shown by 1, 2, 3) at 6 months. 29 After the 6 months, pain index scores for the fluoxetine group decreased from 135 (baseline) to 41.3 (SD Ϯ 63.8; p ϭ 0.001). The placebo group pain index was 98 at baseline and 61.1 at 6 months (SD Ϯ 57.7; p ϭ 0.07); however, differences were noted between treatment groups for baseline measures. 
mg Ϫ2 days; placebo Ϫ1 day; Kruskal-Wallis ϭ 10.306, df ϭ 2; p Ͻ 0.006). 30 All 3 groups showed decreased headache severity and duration from baseline; no differences were observed between treatment groups for these endpoints. The most common AEs were nausea (41%), vomiting (27%), and drowsiness (27%). Fourteen percent of patients receiving venlafaxine withdrew because of AEs.
A Class II trial assessed the efficacy of venlafaxine vs amitriptyline; both were effective in reducing attack frequency (venlafaxine: baseline ϭ 4. 15 31 Patients taking venlafaxine experienced nausea/vomiting (23%) and tachycardia (15%); 1 patient withdrew because of AEs. Patients taking amitriptyline reported hypersomnolence (80%), dry mouth (69%), and concentration difficulties (54%).
Tricyclic antidepressants. The original guideline concluded amitriptyline was established as effective for migraine prevention; that evidence has since been downgraded to Class II (all 3 studies had Ͼ20% dropout rates). Comparative studies of amitriptyline with topiramate 21, 22 and venlafaxine 31 (reviewed above) report similar efficacy at the doses tested.
Conclusions. There is conflicting Class II evidence for use of fluoxetine. Venlafaxine is probably effective for migraine prevention (1 Class I study) and is possibly as effective as amitriptyline in migraine prevention (1 Class II study). Amitriptyline is probably effective for migraine prevention (multiple Class II studies); it is probably as effective as topiramate (2 Class II studies) and possibly as effective as venlafaxine (1 Class II study) for migraine prevention.
␤-Blockers. Metoprolol. The original guideline concluded metoprolol was probably effective in migraine prevention. We reclassified these studies as Class I using the revised AAN criteria.
One new Class II study reported metoprolol (200 mg/day) was more effective than aspirin (300 mg/ day) in achieving 50% migraine frequency reduction (responder rate metoprolol ϭ 45.2%; aspirin ϭ 29.6%; mean difference 15.65; CI 4.43-26.88). 32 Attack frequencies (attacks/month) at placebo run-in and week 20 are 3.36 to 2.37, respectively, for aspirin and 3.55 to 1.82, respectively, for metoprolol. No significant AEs were reported.
A small Class II study reported metoprolol (47.5-142.5 mg/day) had similar efficacy to nebivolol 5 mg/day for migraine prevention (assessed by a decrease in mean migraine attacks). Propranolol. The original guideline concluded propranolol was established as effective for migraine prevention.
In a Class II study, propranolol (80 mg/day) was more effective than placebo and as effective as cyproheptadine (4 mg/day) in reducing migraine frequency, duration, and attack severity. 34 The difference in attack frequency reduction was significant between treatments: propranolol Ϫ2.85 Ϯ 0.2 (SEM) vs cyproheptadine Ϫ3.09 Ϯ 0.31 vs combination 3.12 Ϯ 0.1 vs placebo Ϫ1.77 Ϯ 0.44 (all p Ͻ 0.05 vs placebo). For attack frequency reduction, combination therapy was more effective than monotherapy ( p Ͻ 0.05). AEs were drowsiness, sleep disturbance, weight gain, fatigue, and dry mouth; percentages of patients affected were not reported.
Conclusions. Metoprolol is established as effective for migraine prevention (2 Class I studies) and is possibly as effective as nebivolol or aspirin for migraine prevention (1 Class II study each). Propranolol is established as effective for migraine prevention (multiple Class I studies) and is possibly as effective as cyproheptadine for migraine prevention (1 Class II study).
Calcium-channel blockers. The original guideline concluded that verapamil and nimodipine were probably effective for migraine prevention. The original studies on verapamil and nimodipine were found to have conflicting Class III evidence on the basis of current classification criteria and were downgraded accordingly, yielding Level U recommendations.
Conclusions. Data from older studies regarding verapamil and nimodipine are insufficient when current AAN classification criteria are applied.
Direct vascular smooth muscle relaxants. The original guideline concluded cyclandelate was probably effective for migraine prevention.
Cyclandelate. Two new Class II studies reported conflicting results. The first study showed cyclandelate to be no more effective than placebo in reducing migraine days, attacks, or duration. 35 The second study (smaller, underpowered; n ϭ 25) found cyclandelate significantly reduced the number of migraine days and duration (assessed using a contingent negative variation measure). 36 Conclusions. The efficacy of cyclandelate is unknown (conflicting Class II studies).
Triptans. Since the original guideline, new Class I studies have assessed the efficacy of frovatriptan, 37, 38 naratriptan, 39 and zolmitriptan 40 for short-term prevention of menstrually associated migraine (MAM).
Frovatriptan. Frovatriptan 2.5 mg BID/qd was more effective than placebo in reducing migraine fre-quency. 37 The mean number of headache-free perimenstrual periods (PMPs) per patient (primary endpoint) was higher in the 2 frovatriptan groups (2.5 mg qd ϭ 0. 38 also reports the MAM headache incidence during the 6-day PMP was 67% for placebo, 52% for frovatriptan 2.5 mg QD ( p Ͻ 0.0001 vs placebo), and 41% for frovatriptan 2.5 mg BID ( p Ͻ 0.0001 vs placebo; p Ͻ 0.0001 vs QD regimen). The AE incidence and type for both regimens were similar to those for placebo. The overall AE incidence for frovatriptan was 4.1% (2.5 mg BID) and 2.7% (2.5 mg qd) higher than during placebo treatment.
Naratriptan. In a Class I study, 1 mg BID (given for 5 days, starting 2 days before menses onset) reduced the number of perimenstrual migraine attacks and migraine days. 39 Patients treated with naratriptan 1 mg experienced more headache-free PMPs than those on placebo (50% vs 25%, p ‫؍‬ 0.003). Naratriptan 1 mg reduced the number of MAMs (2.0 vs 4.0, p Ͻ 0.05) and MAM days (4.2 vs 7.0, p Ͻ 0.01) vs placebo. The AE incidence and severity were similar to those of placebo; Ͻ10% of patients experienced dizziness, chest pain, or malaise.
Zolmitriptan. One Class I study reported the efficacy of zolmitriptan 2.5 BID/TID vs placebo. Both zolmitriptan regimens demonstrated superior efficacy vs placebo: the proportion of patients with a Ն50% MAM attack frequency reduction (zolmitriptan 2.5 mg TID [58.6%], p ϭ 0.0007 vs placebo; zolmitriptan 2.5 mg BID [54.7%], p ϭ 0.002 vs placebo; placebo 37.8%). 40 AEs were considered possibly treatment-related in 28 patients (33.3%) in the zolmitriptan 2.5 mg TID group, 29 (36.3%) in the zolmitriptan 2.5 mg BID group, and 18 (22.0%) in the placebo group. The most common AEs were asthenia, headache, dizziness, and nausea.
Conclusions. Frovatriptan is established as effective for the short-term prevention of MAMs (2 Class I studies). Zolmitriptan and naratriptan are probably effective for the short-term prevention of MAMs (1 Class I study each). The utility of these agents in receiving a separate indication for pure menstrual migraine is currently being deliberated by US regulatory authorities.
Other agents. Since the original guideline, additional studies have been identified that assess the efficacy of a carbonic anhydrase inhibitor and a neurokinin inhibitor for migraine prevention.
Carbonic anhydrase inhibitor. In a single Class II study, acetazolamide 250 mg BID was no more effective than placebo in reducing migraine frequency, duration, and severity. e1 This trial (n ϭ 53) was stopped prematurely because of a high number of withdrawals (34%), primarily due to acetazolamide-associated AEs, including paresthesias and asthenia.
Conclusions. The efficacy of acetazolamide is unknown at this time (1 Class II study terminated early). • Lamotrigine Level B negative. The following medication is probably ineffective and should not be considered for migraine prevention:
RECOMMENDATIONS
• Clomipramine Level C negative. The following medications are possibly ineffective and may not be considered for migraine prevention:
CLINICAL CONTEXT Evidence to support pharmacologic treatment strategies for migraine prevention indicates which treatments might be effective but is insufficient to establish how to choose an optimal therapy. Consequently, although Level A recommendations can be made for pharmacologic migraine prevention, similar evidence is unavailable to help the practitioner choose one therapy over another. Treatment regimens, therefore, need to be designed case by case, which may include complex or even nontraditional approaches. Moreover, decision-making must remain with the physician and the patient to determine the optimal therapy, accounting for efficacy, AEs, coexisting/comorbid conditions, and personal considerations. Often trial and error is needed.
Evidence is also unavailable for making broad-range comparisons among multiple agents within a single class; such evidence would provide a more comprehensive understanding of relative efficacy and tolerability profiles across a broader range of therapeutic agents. Studies are needed that specifically evaluate when preventive therapy is warranted and how medications should be titrated. Table e-1 lists some specific consensus-based clinical circumstances wherein considering preventive therapy would be reasonable. A shortcoming of migraine prevention clinical studies is the relatively brief treatment duration (often only 12-16 weeks). Long-term assessment of the efficacy and safety of migraine preventive treatments is needed. Additionally, overall cost is a consideration when prescribing medications; cost may influence compliance, especially long-term.
It seems reasonable that a clinician be mindful of comorbid and coexistent conditions in patients with migraine, to maximize potential treatment efficacy and minimize AE risk. Table e-2 identifies which therapies to consider or avoid when common migraine coexisting conditions are present. Because migraine is frequent in women of childbearing age, the potential for adverse fetal effects related to migraine prevention strategies is particularly concerning.
Evidence from the 2 Class I frovatriptan studies meets the AAN threshold for a Level A recommendation for short-term use to prevent menstrual migraine (reduction in MAM headache incidence by 26% on 2.5 mg BID). However, the Food and Drug Administration questions whether the benefit demonstrated is clinically meaningful and has not approved frovatriptan for this indication.
RECOMMENDATIONS FOR FUTURE RESEARCH Although many preventive therapies reviewed herein are rated as Level C or U on the basis of the quality of evidence available, for some treatments extensive clinical experience supports a possible role in migraine prevention. Many of the older approaches to treating episodic migraine lack the financial justification for high-quality clinical study because they are not currently patentable drugs or otherwise do not promise a financial return for the cost of a major study. Until such treatments can be accurately studied, practitioners are cautioned not to discount these agents because Class I prospective clinical studies are lacking. A case-by-case evaluation of these agents as treatment options is prudent. Future directions should include validating these initial clinical observations in scientifically sound RCTs.
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DISCLAIMER
This statement is provided as an educational service of the American Academy of Neurology and the American Headache Society. It is based on as assessment of current scientific and clinical information. It is not intended to include all possible proper methods of care for a particular neurologic problem or all legitimate criteria for choosing to use a specific procedure. Neither is it intended to exclude any reasonable alternative methodologies. The AAN and the AHS recognize that specific patient care decisions are the prerogative of the patient and the physician caring for the patient, based on all of the circumstances involved. The clinical context section is made available in order to place the evidence-based guideline(s) into perspective with current practice habits and challenges. No formal practice recommendations should be inferred.
